Gliclazide for the treatment of type 2 diabetes mellitus

Published on 03 May 2017
Last Updated on 03 May 2017

Guidance Recommendations

Following an evaluation of gliclazide for the treatment of type 2 diabetes mellitus, gliclazide 80mg immediate release tablet is recommended for listing on the MOH Standard Drug List 1 (SDL1) by the MOH Drug Advisory Committee in view of its better safety profile compared to other sulfonylureas and low annual cost of subsidy.

This recommendation means that subsidies will apply to gliclazide 80mg immediate release tablet for the indications registered in Singapore:

• Non-insulin-dependent diabetes, in association with an adapted diet, in cases where dietary measures alone provide inadequate control of blood glucose levels.

Gliclazide 60mg modified release tablet is not recommended for listing on the MOH Standard Drug List in view that there is no difference in clinical outcomes for the modified release tablet compared with the immediate release tablet to justify the significant cost difference between the two preparations.

Gliclazide for T2DM (May 2017) [PDF, 564 KB]